Browse Category

NASDAQ:VRDN News 15 December 2025 - 14 January 2026

Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline

Viridian Therapeutics stock jumps to a 52-week high as VRDN traders zero in on June FDA deadline

New York, January 14, 2026, 14:14 EST — Regular session Viridian Therapeutics shares climbed 6.4% to $34.03 in early afternoon trading on Wednesday, after hitting an intraday high of $34.25, a new 52-week peak. The gain bucked a softer market. The Invesco QQQ Trust, a proxy for the Nasdaq 100, was down about 1.5%, while the SPDR S&P 500 ETF…
Viridian Therapeutics, Inc. (VRDN) Stock Surges on Dec. 15, 2025: Latest News, Analyst Forecasts, and 2026 Catalysts

Viridian Therapeutics, Inc. (VRDN) Stock Surges on Dec. 15, 2025: Latest News, Analyst Forecasts, and 2026 Catalysts

Viridian Therapeutics, Inc. stock (Nasdaq: VRDN) is back in the spotlight on December 15, 2025, as shares push to fresh highs amid a mix of sector news, new Wall Street coverage, and a shifting competitive landscape in thyroid eye disease (TED)—the company’s core focus. As of 9:47 a.m. ET (14:47 UTC), VRDN stock traded at $33.84, up about 4.7% on…

Stock Market Today

  • Australian Shares Drop as GrainCorp Forecasts Sharp Earnings Decline for Fiscal 2026
    February 2, 2026, 1:16 AM EST. Australian shares fell 1.02%, with the S&P/ASX 200 closing at 8,778.60, slipping below its 125-day moving average amid gold and silver price volatility influenced by US Fed chair nomination news. GrainCorp projected fiscal 2026 underlying earnings before interest, taxes, depreciation, and amortization (EBITDA) between AU$200 million and AU$240 million, down from AU$308 million in fiscal 2025, leading to a 13% drop in its shares. Domestic data showed the S&P Global Australia Manufacturing PMI reached 52.3 in January, the fastest growth in five months. The Melbourne Institute reported annual headline inflation at 3.6%, pushed by higher housing and education costs. Catalyst Metals appointed Mark Connelly as non-executive chair. Recce Pharmaceuticals shares rose over 7% after partnering with the U.S. Army on burn wound infection research.
Go toTop